Gross Profit Trends Compared: Bristol-Myers Squibb Company vs Arrowhead Pharmaceuticals, Inc.

Pharma Giants vs. Innovators: A Decade of Profit Trends

__timestampArrowhead Pharmaceuticals, Inc.Bristol-Myers Squibb Company
Wednesday, January 1, 201417500011947000000
Thursday, January 1, 201538200012651000000
Friday, January 1, 201615833314481000000
Sunday, January 1, 20173140770914710000000
Monday, January 1, 20181614232116014000000
Tuesday, January 1, 201916879557718067000000
Wednesday, January 1, 20208799206630745000000
Friday, January 1, 202113828700036445000000
Saturday, January 1, 202223281000036022000000
Sunday, January 1, 202324073500034313000000
Monday, January 1, 2024355100036351000000
Loading chart...

Infusing magic into the data realm

A Tale of Two Companies: Gross Profit Trends Over a Decade

In the ever-evolving pharmaceutical industry, understanding financial trends is crucial. Over the past decade, Bristol-Myers Squibb Company and Arrowhead Pharmaceuticals, Inc. have shown contrasting trajectories in their gross profits. Bristol-Myers Squibb, a giant in the sector, consistently reported robust profits, peaking in 2021 with a staggering 36 billion dollars. This represents a growth of over 200% from 2014. In contrast, Arrowhead Pharmaceuticals, a smaller player, has seen a more volatile journey. Starting with modest figures in 2014, they experienced a significant surge in 2022, reaching approximately 232 million dollars, marking a dramatic increase of over 130,000% from their 2014 figures. However, 2024 data for Bristol-Myers is missing, leaving a gap in the comparison. These trends highlight the dynamic nature of the pharmaceutical industry, where established giants and emerging innovators navigate their paths to success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025